Quintrio
Home

MEDICINAL CHEMICALS & BOTANICAL PRODUCTS

USANA Health Sciences Inc

USNA

Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).

Last trade $13.68
Day change +$0.135 (+1.00%)
Day range $13.16 – $13.79
Volume 56,333
Market cap $250M

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$250.34M
Price / earnings
—
Price / book
0.48×
Price / sales
0.28×
EV / sales
0.08×
EV / EBITDA
1×

Profitability

Earnings per share
-$1.15
Return on assets
-2.99%
Return on equity
-4.02%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.59×
Quick ratio
1.84×
Cash ratio
1.59×

Cash flow

Price / cash flow
6.01×
Price / free cash flow
8.48×
Free cash flow
$29.54M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for USNA, quarterly periods
Line itemQ3 FY2026 Oct 3, 2026Q2 FY2026 Jul 4, 2026Q1 FY2026 Apr 4, 2026Q4 FY2025 Jan 3, 2026Q3 FY2025 Sep 27, 2025Q2 FY2025 Jun 28, 2025Q1 FY2025 Mar 29, 2025Q4 FY2024 Dec 28, 2024
Revenue$205.89M$223.27M$250.22M$226.2M$213.67M$235.85M$249.54M$213.61M
Cost of revenue$48.72M$48.34M$59.44M$49.41M$48.82M$50.18M$52.45M$38.55M
Gross profit$157.17M$174.93M$190.78M$176.79M$164.86M$185.66M$197.09M$175.06M
Selling, general and administrative$86.73M$82.32M$88.25M$78.08M$85.95M$81.91M$91.44M$73.35M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$158.62M$165.79M$176.91M$172.97M$163.63M$168.95M$181.42M$166.85M
Operating income-$1.45M$9.14M$13.87M$3.82M$1.22M$16.72M$15.67M$8.21M
Interest expense-$38K$0-$240K-$123K-$49K-$259K-$411K-$129K
Income before taxes-$804K-$18.9M$15.47M$4.18M$1.79M$18.82M$16.74M$10.43M
Income taxes$6.09M$9.05M$8.51M$5.77M$8.46M$8.37M$7.45M$5.95M
Net income-$6.89M-$27.95M$6.96M-$1.6M-$6.66M$10.44M$9.29M$4.48M
Net income attributable to common shareholders-$5.56M-$21.38M$7.52M-$1.78M-$6.52M$9.66M$9.4M$4.45M
EBITDA$6.67M$16.82M$22.15M$25.81M$9.14M$24.46M$24.01M$12.21M
Basic earnings per share-$0.30-$1.16$0.41-$0.10-$0.36$0.52$0.49$0.23
Diluted earnings per share-$0.30-$1.16$0.41-$0.10-$0.36$0.52$0.49$0.23

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

USANA Health Sciences (USNA) Reports Q3 Loss, Lags Revenue Estimates

USANA Health Sciences reported a quarterly loss of $0.11 per share, matching consensus estimates but missing revenue expectations with $205.89 million versus the estimated $218.09 million. The company has underperformed the S&P 500 by 35.2% year-to-date. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market near-term.

The Motley Fool

Why Usana Health Sciences Stock Plummeted This Week

Usana Health Sciences stock declined 30% this week following disappointing Q2 results. The company reported adjusted earnings of $0.07 per share and sales of $223 million, both significantly below analyst expectations. Usana announced a $29 million goodwill impairment charge on its Hiya business and revised full-year guidance to expect an $11 million loss instead of a $20-27 million profit. Full-year sales guidance was also lowered from $925-1 billion to $910 million.

Benzinga

Format Innovation Reshapes a $438B Functional Market

The global functional food and beverage market is projected to reach $438 billion in 2026, with oral pouches and alternative caffeine delivery formats driving growth. Doseology Sciences launched caffeine-based energy pouches under its Feed That Brain brand, while Kraft Heinz introduced the HEINZ KegChup, Tilray Brands expanded spirits distribution in Illinois, Cronos Group launched Lord Jones cannabis in Israel, and USANA Health Sciences reported strong 2025 sales with positive 2026 guidance.

Benzinga

The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings

The global consumer healthcare market is experiencing a structural shift where regulatory compliance and FDA approval have become critical competitive advantages. Major companies including Philip Morris, Celsius Holdings, USANA Health Sciences, and Medifast are advancing strategic initiatives focused on regulatory readiness, product integration, and market expansion. Doseology Sciences has partnered with McKinney Regulatory Science Advisors to strengthen its FDA pathway for oral pouch products.

GlobeNewswire Inc.

Women Health & Beauty Supplements Market Analysis and Growth Forecast 2026-2030

The global women's health and beauty supplements market is experiencing robust growth, expanding from USD 62.42 billion in 2024 to USD 66.38 billion in 2025, with projections to reach USD 91.42 billion by 2030 at a CAGR of 6.56%. Key growth drivers include ingredient innovation (collagen, probiotics, adaptogens), format evolution (gummies, powders), direct-to-consumer engagement, and regional localization strategies. The market is characterized by a mixed ecosystem of legacy manufacturers, emerging digital brands, and ingredient innovators leveraging strategic partnerships for competitive advantage.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 22, 20162-for-1stock dividend
Oct 23, 20032-for-1forward split